According to international literature, the mortality of patients diagnosed with TB-HLH who did not receive ATT is reported to be 100%, whereas ATT in combination with immunotherapy can reduce the mortality rate by 40% to 60%. Due to the long-term characteristics and efficacy of ATT, the utility of sufficient immunotherapy at an early stage of treatment is important to suppress cytokine storm in patients with HLH. Patients who received immunotherapy also experienced significantly higher overall survival rates than patients who did not receive ATT.[1,9,14–16]